Cargando…

Current Practice of Percutaneous Coronary Intervention in Patients With Coagulation Disorders

Acute coronary artery disease represents the leading cause of death worldwide. Some studies have shown that coagulation disorders can play a protective role against ischemic heart disease, presumably due to hypocoagulable state and decrease thrombin formation. However, autopsy reports showed atheros...

Descripción completa

Detalles Bibliográficos
Autores principales: El Khoury, Michel, Karam, Boutros, Tabet, Rabih, Lafferty, James C, Snyder, Stavros Thomas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8545607/
https://www.ncbi.nlm.nih.gov/pubmed/34722061
http://dx.doi.org/10.7759/cureus.18284
_version_ 1784590035365920768
author El Khoury, Michel
Karam, Boutros
Tabet, Rabih
Lafferty, James C
Snyder, Stavros Thomas
author_facet El Khoury, Michel
Karam, Boutros
Tabet, Rabih
Lafferty, James C
Snyder, Stavros Thomas
author_sort El Khoury, Michel
collection PubMed
description Acute coronary artery disease represents the leading cause of death worldwide. Some studies have shown that coagulation disorders can play a protective role against ischemic heart disease, presumably due to hypocoagulable state and decrease thrombin formation. However, autopsy reports showed atherosclerotic lesions in some patients with hemophilia. Since the introduction of clotting factors and replacement therapies, the life expectancy of patients with coagulation disorders has increased significantly. As a result, the incidence of cardiovascular diseases became higher making their treatment more challenging. Door to balloon strategy applies in ST-elevation myocardial infarction (STEMI), and percutaneous coronary intervention should not be delayed. While in non-STEMI (NSTEMI) and unstable angina, a hematology consult is essential. Prophylactic coagulation factor replacement is crucial in these patients in order to avoid bleeding complications, but on the other hand, these factors were also associated with thrombotic complications. Historically, bare-metal stents were preferred over drug-eluting stents in view of the shorter duration of dual antiplatelets therapy (DAPT). Currently, some trials have demonstrated the safety of new-generation drug-eluting stents in patients with elevated bleeding risk, where DAPT use is limited to four weeks. The radial artery is the preferred access and was found to have less bleeding complications when compared to the femoral access. Anticoagulation with heparin is the safest in view of antidote availability and shorter half-life. Bivalirudin has also been used in some case reports, while GP2b3a inhibitors are usually avoided except in a high thrombus burden. Close peri procedural follow-up is important with patient education about symptoms of bleed. Carefully and individually tailored antithrombotic and factor replacement therapy is required to overcome these clinically challenging situations. Early screening for cardiovascular risk factors and considering early intervention and management might help to improve the general health status of this population and reduce morbidity.
format Online
Article
Text
id pubmed-8545607
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Cureus
record_format MEDLINE/PubMed
spelling pubmed-85456072021-10-28 Current Practice of Percutaneous Coronary Intervention in Patients With Coagulation Disorders El Khoury, Michel Karam, Boutros Tabet, Rabih Lafferty, James C Snyder, Stavros Thomas Cureus Cardiology Acute coronary artery disease represents the leading cause of death worldwide. Some studies have shown that coagulation disorders can play a protective role against ischemic heart disease, presumably due to hypocoagulable state and decrease thrombin formation. However, autopsy reports showed atherosclerotic lesions in some patients with hemophilia. Since the introduction of clotting factors and replacement therapies, the life expectancy of patients with coagulation disorders has increased significantly. As a result, the incidence of cardiovascular diseases became higher making their treatment more challenging. Door to balloon strategy applies in ST-elevation myocardial infarction (STEMI), and percutaneous coronary intervention should not be delayed. While in non-STEMI (NSTEMI) and unstable angina, a hematology consult is essential. Prophylactic coagulation factor replacement is crucial in these patients in order to avoid bleeding complications, but on the other hand, these factors were also associated with thrombotic complications. Historically, bare-metal stents were preferred over drug-eluting stents in view of the shorter duration of dual antiplatelets therapy (DAPT). Currently, some trials have demonstrated the safety of new-generation drug-eluting stents in patients with elevated bleeding risk, where DAPT use is limited to four weeks. The radial artery is the preferred access and was found to have less bleeding complications when compared to the femoral access. Anticoagulation with heparin is the safest in view of antidote availability and shorter half-life. Bivalirudin has also been used in some case reports, while GP2b3a inhibitors are usually avoided except in a high thrombus burden. Close peri procedural follow-up is important with patient education about symptoms of bleed. Carefully and individually tailored antithrombotic and factor replacement therapy is required to overcome these clinically challenging situations. Early screening for cardiovascular risk factors and considering early intervention and management might help to improve the general health status of this population and reduce morbidity. Cureus 2021-09-25 /pmc/articles/PMC8545607/ /pubmed/34722061 http://dx.doi.org/10.7759/cureus.18284 Text en Copyright © 2021, El Khoury et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Cardiology
El Khoury, Michel
Karam, Boutros
Tabet, Rabih
Lafferty, James C
Snyder, Stavros Thomas
Current Practice of Percutaneous Coronary Intervention in Patients With Coagulation Disorders
title Current Practice of Percutaneous Coronary Intervention in Patients With Coagulation Disorders
title_full Current Practice of Percutaneous Coronary Intervention in Patients With Coagulation Disorders
title_fullStr Current Practice of Percutaneous Coronary Intervention in Patients With Coagulation Disorders
title_full_unstemmed Current Practice of Percutaneous Coronary Intervention in Patients With Coagulation Disorders
title_short Current Practice of Percutaneous Coronary Intervention in Patients With Coagulation Disorders
title_sort current practice of percutaneous coronary intervention in patients with coagulation disorders
topic Cardiology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8545607/
https://www.ncbi.nlm.nih.gov/pubmed/34722061
http://dx.doi.org/10.7759/cureus.18284
work_keys_str_mv AT elkhourymichel currentpracticeofpercutaneouscoronaryinterventioninpatientswithcoagulationdisorders
AT karamboutros currentpracticeofpercutaneouscoronaryinterventioninpatientswithcoagulationdisorders
AT tabetrabih currentpracticeofpercutaneouscoronaryinterventioninpatientswithcoagulationdisorders
AT laffertyjamesc currentpracticeofpercutaneouscoronaryinterventioninpatientswithcoagulationdisorders
AT snyderstavrosthomas currentpracticeofpercutaneouscoronaryinterventioninpatientswithcoagulationdisorders